Introduction {#Sec1}
============

Acute lower respiratory infections (ALRIs) are a major cause of morbidity and the leading infectious cause of death in children younger than 5 years on a global scale. They represent an important health and social problem due to the associated large number of doctors' office visits, hospitalizations, work hours lost by parents, and enormous medical and socio-economic costs. A systematic review estimated that, in 2010, 11.9 million episodes of severe and 3 million episodes of very severe ALRIs resulted in hospital admissions of young children worldwide \[[@CR1]\]. Based on pathophysiologic processes, ALRIs can be divided into bronchiolitis and pneumonia. Bronchiolitis affects the smallest branches of the bronchial tree in children \< 2 years of age and most often has viral etiology, whereas pneumonia can be caused by bacteria, viruses, or other pathogens \[[@CR2]\]. A wide range of different viruses can cause ALRI of varying severity \[[@CR3]\]. Strong similarities in the clinical manifestations of different viral infections make diagnosis based on clinical parameters unreliable. The use of sensitive nucleic acid--based molecular techniques in current laboratory practice allows rapid and accurate etiological diagnosis, which can help in clinical decision making and may assist in measures to prevent nosocomial transmission.

Influenza viruses cause annual epidemics, during which 5--10% of adults and 20--30% of children are affected \[[@CR4]\]. Children aged under 5 years, particularly children aged \< 2 years, are a major risk group for severe influenza and complications. It was estimated that, in 2008, 20 million cases of influenza-associated ALRI and 1 million cases of influenza-associated severe ALRI occurred worldwide in children younger than 5 years \[[@CR5]\]. Respiratory syncytial virus (RSV) is a common cause of ALRI in infants and young children and is the most frequently identified pathogen in cases of bronchiolitis. In 2015, this virus caused 33.1 million episodes of ALRI worldwide and resulted in approximately 3.2 million hospital admissions and 59,600 in-hospital deaths in children younger than 5 years \[[@CR6]\]. Human metapneumovirus (hMPV) is closely related to RSV in its structural, epidemiologic, and clinical characteristics, with disease severity similar or less than RSV \[[@CR7], [@CR8]\]. Human parainfluenza virus (PIV) types 1 and 2 are major etiologic agents of laryngotracheobronchitis (croup); PIV-3 and to a lesser extent PIV-1 are frequently associated with bronchiolitis and pneumonia in infants and young children \[[@CR9]\]. The clinical spectrum of human rhinovirus (RV) infections ranges from a mild upper respiratory tract illness to severe pneumonia, and a significant proportion of the infections (\~1/3) are asymptomatic. Rhinoviral ALRIs in early childhood, such as RSV infections, are associated with recurrent wheezing and asthma later in life \[[@CR10]\]. Human adenoviruses (AdV) cause a wide range of respiratory diseases of variable severity and are a particular problem in immunocompromised children \[[@CR11]\]. The human bocaviruses (BoV) are characterized by high levels of co-infections \[[@CR12]\].

The aim of this study was to determine the incidence of 11 of the most common respiratory viruses, namely influenza viruses, RSV, hMPV, PIV 1/2/3, RV, AdV, and BoV, among children aged 0 to 5 years with ALRI and to characterize the epidemiologic features of infections during three successive epidemic seasons.

Materials and methods {#Sec2}
=====================

Study population and specimen collection {#Sec3}
----------------------------------------

This study started in October 2015 and covered three consecutive winter seasons (2015/2016, 2016/2017, and 2017/2018). Patients were recruited from October to May inclusively. In 2017, surveys were made all year round. The study population comprised children aged 0--5 years from different regions of Bulgaria treated for ALRI (bronchiolitis or pneumonia) in primary care settings or hospitals. Written informed consent from parent/guardian was obtained before enrollment. Children were only once included in the study. The diagnosis of each patient was determined by their attending pediatric physician based on standard clinical criteria. Bronchiolitis was defined as a combination of clinical symptoms and signs occurring in children aged less than 2 years including a viral upper respiratory infection prodrome, progressing to cough, tachypnea, expiratory dyspnea, prolonged expiration, and wheezing from a distance. Pneumonia was diagnosed based on clinical manifestations and X-ray changes. Diagnostic tests that were performed included blood analyses---complete blood count with differential picture and C-reactive protein (CRP). Chest X-ray and bacterial cultures of respiratory specimens were performed only in children with clinical suspicion of bacterial complication. The patients with suspected viral etiology of illness (normal or slightly elevated white cell count and CRP) were selected. Children were excluded from the study if they had the following: (a) an underlying medical conditions increasing the risk of respiratory infections, including prematurity, bronchopulmonary dysplasia, cystic fibrosis, congenital heart disease, and neurological or metabolic disease such as diabetes mellitus, hemoglobinopathies, immunosuppression, malignances; (b) hospitalization for any cause within the preceding 30 days.

Both nasopharyngeal and throat specimens were prospectively collected from all enrolled children (2 swabs per child) with the help of commercial polyester swabs (Deltalab, Spain) during the visit to the doctor or within the first 24 h of admission. The specimens were collected within 7 days of the respiratory symptoms onset. After collection, specimens accompanied with demographic data and clinical diagnosis were promptly transported with ice packs to the National Laboratory "Influenza and ARD" for viral respiratory pathogen detection. If immediate delivery was not possible, the samples were stored in a refrigerator (4--8 °C) for no more than 48 h. In the laboratory, both swabs from each child were stirred into a single tube containing 2 ml of sterile phosphate buffered saline (PBS) and antibiotics. The specimens were processed immediately or stored at − 80 °C before testing.

Extraction of nucleic acids and real-time RT-PCR {#Sec4}
------------------------------------------------

Viral nucleic acids were extracted automatically from respiratory specimens using a commercial ExiPrep Dx Viral DNA/RNA kit (Bioneer, Korea) in accordance with the manufacturer's instructions. The detection and typing/subtyping of influenza viruses were carried out by a real-time RT-PCR method and the SuperScript III Platinum® One-Step qRT-PCR System (Invitrogen, Thermo Fisher Scientific, USA). Primers and probes were provided by the International Reagent Resource (IRR, USA). All samples were first tested for the presence of influenza A and B viruses. Those that were positive for influenza A were subsequently screened for A(H1N1)pdm09 and A(H3N2). The genetic lineage of detected influenza B viruses was also determined by real-time RT-PCR. Amplification was performed using a Chromo 4 thermal cycler (Bio-Rad Laboratories, Inc., USA) in accordance with the protocol of CDC-Atlanta \[[@CR13]\]. The detection of RSV, hMPV, PIV 1/2/3, RV, AdV, and BoV was performed using singleplex real-time PCR assays and an AgPath-ID One-Step RT-PCR kit (Applied Biosystems, Thermo Fisher Scientific, USA). The primers, probes, and thermocycling conditions used in the study were identical to those previously described \[[@CR14], [@CR15]\]. Positive and negative controls were included in each run. For influenza type A and type B viruses, positive controls were provided by IRR, USA; for other targets, AmpliRun DNA/RNA Amplification Controls (Vircell, Spain) were used. Clinical specimens were tested in a separate real-time RT-PCR reaction for the RNAase-P gene, which provided verification of RNA integrity and the absence of PCR inhibition \[[@CR13]\]. Subgroup-specific primers and probes targeting the RSV F and N genes were used for multiplex real-time RT-PCR to distinguish RSV-A from RSV-B, respectively, as described previously \[[@CR16]\].

Statistics {#Sec5}
----------

Age, gender, clinical features, and the incidence of each virus were compared using the chi square or Fisher's exact tests for categorical variables. *p* values \< 0.05 were considered statistically significant.

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

The study population consisted of 515 children aged \< 5 years suffering from ALRI: 112, 191, and 193 in the first, second, and third seasons, respectively, and 19 outside the season in 2017. Only 6 (1.2%) of these children attended outpatient healthcare centers, 509 (98.8%) were hospitalized, and 26 were admitted to intensive care units (ICUs). The patients' ages ranged from 13 days to 59 months (mo) (mean age 21.29 ± 15.20 mo; median age 20 mo). Among the study subjects, 90 (17.5%) were \< 6 mo old, 78 (15.1%) were 6--11 mo old, 117 (22.7%) were 12--23 mo old, and 223 (43.3%) were 24--59 mo old, while 7 (1.4%) were an unknown age. Most children (55.3%) were under 23 mo of age; 306 (59.4%) participants were boys, and 209 (40.6%) were girls.

Respiratory virus identification {#Sec8}
--------------------------------

Viral respiratory pathogens were identified in 402 (78.1%) of the 515 patients examined: 90 (80.4%), 158 (82.7%), and 139 (72%) in the 2015/16, 2016/17, and 2017/18 seasons, respectively, and 15 (78.9%) in the summer of 2017. Single infections were detected in 338 (65.6%) children; co-infections with two and three viruses were found in 58 (11.3%) and 6 (1.2%) children, respectively. In 68 (13.2%) of the examined patients, the following influenza viruses were identified: 25 (4.9%) A(H1N1)pdm09, 22 (4.3%) A(H3N2), and 21 (4.1%) type B (17 B/Yamagata and 4 B/Victoria). The non-influenza viruses RSV, RV, hMPV, AdV, BoV, and PIV1/2/3 were detected in 193 (37.5%), 71 (13.8%), 47 (9.1%), 36 (7%), 36 (7%), and 15 (2.9%) of the examined patients, respectively. The pathogen most frequently identified was RSV, accounting for 48% of the infections with positive viral detection. In the cases of mixed infections, AdV, BoV, and InfA(H3N2) were more common co-infecting viruses, with the combinations RSV/AdV and InfA(H3N2)/RSV being the most frequently identified (Fig. [1](#Fig1){ref-type="fig"}; Table [1](#Tab1){ref-type="table"}).Fig. 1Proportions of single infections and co-infectionsTable 1Number of respiratory viruses, detected as a single pathogen or co-pathogen, in children with ALRI\*A(H1N1) pdm09A(H3N2)Inf typeBRSVhMPVPIV1PIV2PIV3RVAdVBoVDetection rate (%)A(H1N1)pdm09*24*00100000004.9A(H3N2)*13*0600000104.3Inf type B*16*300001104.1RSV*150*100158537.5hMPV*38*1003409.1PIV1*1*001010.8PIV2*1*00000.2PIV3*8*0011.9RV*51*2513.8AdV*17*17.0BoV*20*7.0Co-pathogen in dual infection1753793--2171713Co-pathogen in triple infection--2--6--------323\*Single pathogens are indicated in italics

Among the 193 RSV-positive patients, RSV subgroup A were identified in 57 (29.5%) and RSV subgroup B in 121 (62.7%) patients. RSV-B outnumbered RSV-A over the three seasons. Co-infection with both subgroups of RSV was detected in 9 (4.7%) children. For 6 specimens (3.1%), the subgroup could not be determined due to a low viral load.

Seasonal distribution of viral agents {#Sec9}
-------------------------------------

The greatest number of respiratory viruses was detected in specimens obtained in February 2016 and 2017 and April 2018 (Fig. [2](#Fig2){ref-type="fig"}). The study did not involve BoV testing in the first surveillance period. Influenza virus circulation was observed from December to April during the first two seasons and from December to February during the third season. RSV was identified in specimens collected between January 2015 and April 2016, October 2016 and April 2017, and December 2017 and April 2018. Furthermore, RSV activity peaked in week 5 of 2016, week 7 of 2017, and week 11 of 2018. In 2017, RV and BoV infections were more prevalent in the fall and the spring, whereas hMPV, PIV, and AdV occurred predominantly in the winter-spring seasons.Fig. 2Monthly distribution of respiratory virus detection among children with ALRI

Age and gender distribution {#Sec10}
---------------------------

Viral pathogens were detected in all age groups, and the positive rate in each of the four age groups was 73.3%, 80.8%, 74.4% ,and 80.7% (Fig. [3](#Fig3){ref-type="fig"}). The proportion of influenza-positive children was larger in the 24--59-mo age group (18.8%) compared to 0--23 mo (8.8%) (*p* \< 0.05). The median age of children with influenza A(H1N1)pdm09 (19 mo) and type B (19 mo) infection was slightly higher than that of children with influenza A(H3N2) (17 mo). RSV was the most frequently detected pathogen among children with ALRI in all age groups studied. The prevalence of RSV infection was highest in the youngest age group (\< 6 mo, 50%), followed by 6--11 mo (38.5%). The mean age (± SD) of children with proven RSV infection was 21.05 ± 15.22 mo, and the median age was 20 mo. Of the RSV-positive children with ALRI, 58.5% were under 2 years of age: 61% were boys and 39% were girls (*p* = 0.5773). The detection rates of other respiratory viruses fluctuated among the different age groups, but the differences were not statistically significant. Co-infections were more frequent in the 12--23-mo group (25.3%).Fig. 3Age distribution of children with detected respiratory viruses. Positive cases represent the sum of single infections and co-infections for each virus

Viral detection in children with different clinical diagnoses {#Sec11}
-------------------------------------------------------------

Complications of the lower respiratory tract---bronchiolitis and pneumonia---were analyzed in 328 and 187 patients, respectively. Table [2](#Tab2){ref-type="table"} summarizes the baseline characteristics and the results of viral detection in the group of children with different clinical diagnoses.Table 2Prevalence of viral infections in children with acute lower respiratory tract diseasesBronchiolitisPneumoniaTotal (*n* = 328)Single (*n*, %)Co-detection (*n*, %)*p*Total (*n* = 187)Single (*n*, %)Co-detection (*n*, %)*p*Demographic characteristics Median age in months2020 Gender, male/female ratio199/1290.7732107/80 Hospitalizations, *n* (%)323 (98.5)186 (99.5) Hospitalization in ICU, *n* (%)23 (7.0)3 (1.6)Seasons (*n* = 226 in 2017)151 (66.8)75 (33.2) Winter71 (47)46 (64.8)17 (23.9)39 (52)25 (64.1)9 (23.1) Spring29 (19.2)21 (72.4)2 (6.9)19 (25.3)8 (42.1)4 (21.1) Summer13 (8.6)10 (76.9)1 (7.7)0 Fall38 (25.2)25 (65.8)6 (15.8)17 (22.7)6 (35.3)1 (5.9)Viral etiology, n (%)271 (82.6)226 (68.9)45 (13.7)131 (70.1)112 (59.9)19 (10.2) Influenza A(H1N1)pdm0911 (3.4)10 (3.0)1 (0.3)0.697614 (7.5)14 (7.5)00.22 Influenza A(H3N2)6 (1.8)3 (0.9)3 (0.9)0.059616 (8.6)10 (5.3)6 (3.2)*0.0134* Influenza type B11 (3.4)9 (2.7)2 (0.6)1.00010 (5.3)8 (4.3)2 (1.1)0.6380 Respiratory syncytial virus146 (44.5)115 (35.1)31 (9.5)*0.0330*47 (25.1)35 (18.7)12 (6.4)*0.01* Metapneumovirus30 (9.1)25 (7.6)5 (1.5)1.00017 (9.1)13 (7.0)4 (2.1)0.2716 Parainfluenza virus13 (4)9 (2.7)4 (1.2)0.24052 (1.1)1 (0.5)1 (0.5)0.27 Rhinovirus54 (16.5)37 (11.3)17 (5.2)*0.0020*17 (9.1)14 (7.5)3 (1.6)0.7133 Adenovirus15 (4.6)5 (1.5)10 (3.0)*0.0001*21 (11.2)12 (6.4)9 (4.8)*0.0004* Bocavirus29 (8.8)15 (4.6)14 (4.3)*0.0001*7 (3.7)5 (2.7)2 (1.1)0.2681*P* values \< 0.05 are indicated in italic

Patients with different clinical diagnoses did not differ significantly in terms of age. Bronchiolitis and pneumonia cases occurred mainly during the winter season. Viral infections were detected in 271 (82.6%) patients with bronchiolitis and 131 (70.1%) with pneumonia. Among the patients with bronchiolitis, there were 42 cases of dual infections and 3 cases of triple infection; among the patients with pneumonia, there were 16 and 3 dual and triple infections, respectively. The proportion of detected influenza viruses among patients with bronchiolitis was 28 out of 328 (8.5%) and 40 out of 187 (21.4%) for pneumonia. Regarding non-influenza viruses, the proportions were 243/328 (74.1%) and 91/187 (48.7%), respectively. In the cases of pneumonia, influenza viruses were detected more commonly in children aged 24--59 mo as compared to those under 24 mo of age, whereas non-influenza viruses more often caused pneumonia in children under 24 mo of age (*p* \< 0.05). In a 3-year-old child who died of pneumonia and acute respiratory distress syndrome (ARDS), influenza A(H1N1)pdm09 virus was detected. The most common virus associated with bronchiolitis was RSV (*p* \< 0.05), accounting for 44.5% of the cases (115 cases as a single pathogen and 31 cases as part of co-infections), followed by RV (16.5%). Among the children suffering from pneumonia, RSV was also the most prevalent virus (25.1%) (*p* \< 0.05), followed by AdV (11.2%) hMPV and RV (9.1%). In a 2-year-old child with pleuropneumonia and ARDS, RSV-A was detected. RSV and RV were more common pathogens of bronchiolitis than pneumonia, while influenza viruses and AdV were a more frequent cause of pneumonia compared to bronchiolitis (*p* \< 0.05). Influenza A(H1N1)pdm09 and type B viruses, hMPV, and PIV were mostly detected as a single pathogen in cases of bronchiolitis and pneumonia, while AdV, BoV, RV, influenza A(H3N2), and RSV were frequently identified in mixed infections. In cases of bronchiolitis, AdV was more commonly found as a part of mixed infections than as a single pathogen. In 26 children treated in the ICU, 12 (46.2%) RSV, 1 (3.8%) hMPV, 2 (7.7%) PIV, 5 (19.2%) RV, and 5 (19.2%) BoV were detected.

Discussion {#Sec12}
==========

In this prospective study, we evaluated the incidence of the 11 most common respiratory viruses in 0- to 5-year-old children with ALRI in Bulgaria. During the study period, viral infections were detected in 78.1% of the cases of ALRI, with the lowest positive rate in the third season (*p* \< 0.05). In the PCR-based surveys conducted in various countries, the percentages of proven viral infections in cases of ALRI varied greatly, i.e., 83.2% in China \[[@CR17]\], 75.2% in Spain \[[@CR18]\], 50.3% in Brazil \[[@CR19]\], and 36.7% in Turkey \[[@CR20]\], due to differences in climatic and geographic conditions, the study population, and the range of respiratory agents investigated. In our population, the proportion of viral infections in the cases of bronchiolitis and pneumonia was 82.6% and 70.1%, respectively. These results are in agreement with previous reports in which viral pathogens were proven in over 90% of bronchiolitis cases \[[@CR21]--[@CR23]\] and in 43--81% of pneumonia cases \[[@CR24]--[@CR28]\]. Not surprisingly, RSV was the most frequently detected etiologic agent of ALRI, identified in 37.5% of the cases (44.5% in patients with bronchiolitis and 25.1% in patients with pneumonia), with a predominance of RSV subgroup B during the three seasons. RSV is known as a major pathogen in pediatric ALRIs, causing 50--90% of hospitalizations for bronchiolitis, 5--40% of those for pneumonia, and 10--30% of those for tracheobronchitis \[[@CR23], [@CR25], [@CR29]\]. Consistent with other studies, the incidence of RSV infections was highest in the youngest age groups (\< 6 months), which indicates higher susceptibility of this age group to RSV infection, and decreased with increased age due to the development of immunity after repeated infections \[[@CR30]\]. The likelihood of occurrence of RSV infection immediately after birth points to the need for the administration of a RSV vaccine during the last months of pregnancy \[[@CR31]\]. In the past decade, RSV treatments in development have included 10 vaccines and 11 therapeutic agents in active clinical trials \[[@CR32]\].

Children aged \< 5 years have high rates of influenza morbidity, and influenza-related complications and hospitalizations \[[@CR33], [@CR34]\]. In this study, influenza viruses were frequently detected, accounting for 13.2% of the cases. Their incidence rate was higher in the cases of pneumonia (21.4%) than in the cases of bronchiolitis (8.5%) (*p* \< 0.05). With respect to the studied respiratory agents, specific prevention measures, such as vaccination and antiviral treatment, are only available against influenza viruses. Influenza vaccination would reduce greatly the burden of ALRI and prevent the severe forms of illness and deaths, but vaccine coverage in Bulgaria is extremely low (2--3% of the total population).

Human RVs are thought to cause a mild common cold, but they have been increasingly recognized as a significant pathogen of ALRIs in young children \[[@CR10], [@CR27], [@CR35]\]. In a multicenter study involving 2207 children with severe bronchiolitis, RVs were reported as the second most common cause of bronchiolitis after RSV, accounting for 25.6% of the cases \[[@CR21]\]. In another US study, among the 2358 children with pneumonia, RVs were detected in 27% of children \[[@CR27]\]. In our data, RVs were also the second most common viruses in patients with bronchiolitis, detected in 16.5% of the cases (11.3% as a single pathogen).

In the literature, hMPV is a common pathogen in pediatric ALRIs and is second only to RSV as a causative agent of bronchiolitis in early childhood \[[@CR36], [@CR37]\]. HMPV incidence has also been variable in different countries, as it may vary from year to year in the same region. In this study, hMPV was the third most frequent agent of bronchiolitis, identified as a single pathogen in 7.6% of the cases. The total hMPV detection rate of 9.1% was greater than that reported in studies in Spain (5.5%) \[[@CR18]\] and China (6.5%) \[[@CR38]\], and less than the 20% reported in a USA study \[[@CR39]\]. According to other studies, children with single hMPV infections were older compared to those with single RSV infections (21 mo vs 19 mo) \[[@CR7]\].

Studies of childhood ALRIs have reported various detection rates for AdV, i.e., 17% in Spain \[[@CR40]\], 15.8% in Brazil \[[@CR19]\], 11% in the USA \[[@CR27]\], and 5.8% in China \[[@CR41]\]. The proportion of AdV infections found among Bulgarian ALRI children was 7%. AdVs were associated with pneumonia and bronchiolitis as a sole pathogen in 6.4% and 1.5% of the cases, respectively. The high frequency (52.8%) of co-infections involving AdV can be explained by their long shedding period.

Human PIV types 1, 2, 3, and 4 have different clinical and epidemiological characteristics, and the most common cause of ALRI is PIV-3 \[[@CR42]\]. In this study, PIVs occupied a small share in the etiological structure of ALRI---they were identified in 2.9% of the studied children, with a predominance of PIV-3 (2%). Only one child (0.2%) was PIV-2 positive. This PIV positive rate was lower than that reported in a study in Mexico (5.5%) of 1404 children under 5 years of age with pneumonia \[[@CR26]\] and in a study in China (19.58%) of 771 children with ALRI \[[@CR43]\].

Although BoVs have been identified in a significant percentage of children with ALRI in a number of countries \[[@CR24], [@CR44]\], their etiological role has not been elucidated yet. The high incidence (up to 75%) of co-infections involving BoV, as well the high frequency of BoV detection in asymptomatic children, casts doubts on their clinical significance and role as true pathogens \[[@CR12]\]. In this first Bulgarian study of BoV infections, the incidence of BoVs among children with ALRI was 7%. They were detected as a single pathogen in 4.6% and 2.7% of the children with bronchiolitis and pneumonia, respectively. BoVs were also associated with a high rate (44.4%) of co-infections.

In a systematic review, Goka et al. reported that the incidence of mixed viral infections ranged from 5 to 62%, with a mean of 23% \[[@CR45]\]. In this study, the proportion of cases with co-detections was 15.9%. The most common participants in mixed infections were AdV, BoV, A(H3N2), PIV, and RV in which the proportions of co-infections were 52.8%, 44.4%, 40.9%, 33.3%, and 28.2%, respectively. The simultaneous presence of more than one virus in the same sample is difficult to interpret. Highly sensitive PCR assays make it possible to identify very small amounts of viral nucleic acids, which are present during the incubation period or the convalescence phase. The identification of more than one virus can be explained by the prolonged shedding of virus that caused a previous infection, coincidental upper airway infection, or asymptomatic circulation of some viruses. Prolonged BoV shedding has been reported for up to 4.5 months in hospitalized children \[[@CR46]\]. Due to the frequent detection of BoV, RV, AdV, coronaviruses, and enteroviruses in asymptomatic healthy children, their PCR results should be interpreted with caution, especially in the cases of co-detection with other potential pathogens \[[@CR12]\]. In contrast, RSV, influenza viruses, hMPV, and PIV are substantially more frequent in patients with pneumonia than in controls, and their PCR detection is likely to be causative of disease \[[@CR47]--[@CR49]\]. The use of quantitative PCR with assessment of viral load could be helpful for the interpretation of multiple positive PCR results. The clinical significance of mixed infections is still unclear. There are controversial views on the relationship between multiple pathogen infections and disease severity. A few studies have reported that there is no relationship between mixed viral infections and illness severity \[[@CR50]\], while others suggest that co-infections could be associated with a more severe disease course compared to single infections \[[@CR51]\].

In our study, there were some variations in the timing of circulation of the individual viruses. Information about the seasonal distribution of respiratory viruses is important for enacting prophylactic measures among high-risk children and for strengthening control measures to prevent nosocomial infections.

The limitation of this study is that it did not involve testing for human coronaviruses, which can also cause ALRI \[[@CR24], [@CR27]\].

Conclusions {#Sec13}
===========

This study provides important information concerning the participation of the most common respiratory viruses in the development of ALRI in early childhood. It demonstrates the leading role of RSV as a causative agent of bronchiolitis and pneumonia in infants and young children. Our results highlight the importance of enhanced surveillance of respiratory viruses and indicate the urgent need for developing effective prevention strategies and new drug treatments.
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